Document:

Filed by Automated Filing Services Inc. (604) 609-0244 - Nextgen Biosciences Inc. - Exhibit 10.9

EXHIBIT 10.9

CONSULTANCY AGREEMENT

PARTIES

(1) NEXTGEN BIOSCIENCE INC., whose office is located at,
46 Aldgate High Street, EC3N 1AL London, U.K. (the “Company”)

(2) Dr John Savin, of 8 Walnut Drive Wendover, Bucks,
HP22 6RT (the “Consultant”)

WHEREAS

	(A) 	
      The Consultant has agreed to provide consultancy services
      to the Company in the area of scientific advice in connection with the
      business of the evaluation, acquisition and development of patents in the
      field of healthcare drug treatments offered by the Company and its
      associated companies (the “Business”).

	 	 
	(B) 	
      The parties have agreed that this agreement shall govern
      the terms of the services to be provided by the
  Consultant.

OPERATIVE PROVISIONS

	1. 	
      DURATION OF APPOINTMENT

	 	 	 
	1.1 	
      The Consultant shall continue to provide the consultancy
      service to the Company on the terms of this agreement for a term from
      1st December 2007 for a fixed term of two years unless or until
      terminated under the provisions of Clause 5.1 hereafter. The parties may
      extend the term of this Agreement by mutual written agreement.

	 	 	 
	2. 	
      DUTIES

	 	 	 
	2.1 	
      The services of the Consultant shall comprise the giving
      of advice to the Company in the area of scientific advice via the
      Scientific Advisory Board of the Company (“Advisory Board” or “SAB”)) in
      connection with the Business and such other advisory services as may be
      agreed between the parties.

	 	 	 
	2.2 	
      The Consultant agrees to provide up to 2 days per year
      for the performance of the services in clause 2.1 with additional time at
      the sole discretion of the Consultant.

	 	 	 
	2.3 	
      The Consultant shall be accountable to the Company’s CEO
      and shall in performance of his role hereunder:

	 	 	 
		(a) 	
      Use his best endeavours to advise the Company via the
      Advisory Board when required in the areas described in 2.1
above;

	 	 	 
		(b) 	
      Conduct such travelling as shall be reasonably necessary
      to advise the Business; subject to clause 2.2:

	 	 	 
		(c) 	
      Carry out his duties in good faith and in proper and
      efficient manner;

	 	 	 
		(d) 	
      Conduct himself with propriety and not bring the Company
      into disrepute;

	 	 	 
		(e) 	
      Not have any authority to bind the Company in any way and
      shall not hold himself out either by words or conduct as being the agent
      of the Company;

		(f) 	
      Act as a member of the Advisory Board of the Company,
      attending meetings where possible of such advisory board when held in
      London or other cities in Europe subject to 2.2; and

	 	 	 	 
		(g) 	
      Not misrepresent the Company to any person.

	 	 	 	 
	3. 	
      FEES

	 	 	 	 
	3.1 	
      The Consultant shall be not entitled to receive from the
      Company any fixed cash fees for the services outlined herein, but shall be
      entitled to receive reimbursement of any and all expenses properly
      incurred in performing his duties hereunder.

	 	 	 	 
	3.2 	
      The Consultant will receive, as payment in kind from the
      Company, in respect of his services under this Agreement, the issue to him
      as sole beneficial owner of 100,000 shares in the Company and to enter him
      on the register of shareholders. The Consultant has been notified that the
      shares will be issued under US securities laws and will be subject to
      restrictions as set out by the securities and exchanges commission. The
      Company agrees to notify the consultant of any such restrictions that may
      prevent the consultant trading in the Company’s shares.

	 	 	 	 
	4. 	
      CONFIDENTIALITY

	 	 	 	 
	4.1 	
      The Consultant shall not, either during the continuance
      of this agreement or for not less than one year thereafter make personal
      use of or divulge to any other company, firm or person any confidential
      information received by virtue of this Agreement or any market or other
      information relating to the business of the Company.

	 	 	 	 
	5. 	
      TERMINATION

	 	 	 	 
	5.1 	
      This Agreement may be terminated in accordance with
      clause 1 hereof by either party giving one week’s written notice to the
      other party in the following circumstances:

	 	 	 	 
		(a) 	
      if either party is unable to continue performing the
      agreed duties as set out in this agreement for any reason;

	 	 	 	 
		(b) 	
      if either party commits or causes to be committed any
      material breach of its obligations under the Agreement provided that in
      the case of a breach capable of remedy the non-defaulting party shall have
      first given written notice to the defaulting party specifying the breach
      complained of any requiring the same to be remedied within a reasonable
      period of time from notification thereof and the defaulting party shall
      have failed to comply therewith;

	 	 	 	 
		(c) 	
      if either party commits an act of insolvency,
      including:

	 	 	 	 
			i. 	
      making a general assignment for the benefit of, or
      entering into a reorganisation, arrangement, or composition with
      creditors, or

	 	 	 	 
			ii. 	
      admitting in writing that it is unable to pay its debts
      as they become due, or

	 	 	 	 
			iii. 	
      seeking, consenting to or acquiescing in the appointment
      of any trustee, administrator, receiver or liquidator or analogous officer
      of it or any material part of its property, or

	 	 	 	 
			iv. 	
      the presentation or filing of a petition in respect of it
      (other than by the other party to this Agreement in respect of any
      obligation under this Agreement) in any court or before any agency
      alleging or for the bankruptcy, winding-up or insolvency of such party (or
      any

	 		
      analogous proceeding) or seeking any reorganisation,
      arrangement., composition, readjustment, administration, liquidation,
      dissolution or similar relief under any present or future stature, law or
      resolution, such petition (except in the case of a petition for winding-up
      or any analogous proceeding in respect of which no such 30 day period
      shall apply not having been stayed or dismissed within 30 days of its
      filing;

	 	 	 
	 	v. 	
      the appointment of a receiver, administrator, liquidator
      or trustee or analogous officer of such party over all or any material
      part of such party’s property.

	6. 	
      ASSIGNMENT

	 	 
	6.1 	
      This Agreement may not be assigned by either party
      without the prior written consent of the other party.

	 	 
	7. 	
      AMENDMENT

	 	 
	7.1 	
      This Agreement may not be amended except by the written
      consent of both parties.

	 	 
	8. 	
      NOTICES

	 	 
	8.1 	
      All notices required to be delivered under this agreement
      by one party to the other shall be sent in writing to the addresses as are
      set forth at the beginning of this agreement, or such address as the
      parties shall thereafter provide to each other in writing.

	 	 
	9. 	
      GOVERNING LAW

	 	 
	9.1 	
      The Agreement shall be governed by and constructed in
      accordance with the laws of the United States of America. Any disputes
      which may arise out of this Agreement, if not resolved amicably between
      the parties, shall be settled finally before the courts of the United
      States of America.

DATED THE 1st DAY OF December, 2007 

ATTESTATIONS

Signed as a deed by a DIRECTOR or the COMPANY SECRETARY on
behalf of

	  	/s/ David Cooper 
	NEXTGEN BIOSCIENCE INC. 	 
    
	  	  
	Signed as a deed by 	/s/ Dr. John Savin 
	Dr John SavinFiled by Automated Filing Services Inc. (604) 609-0244 - Nextgen Biosciences Inc. - Exhibit 10.10

EXHIBIT 10.10

CONSULTANCY AGREEMENT

PARTIES

(1) NEXTGEN BIOSCIENCE INC., whose office is located at,
46 Aldgate High Street, EC3N 1AL London, U.K. (the “Company”)

(2) Dr. Rolf Witte, Hans-Sachs-Str. 3 in 51375
Leverkusen, Germany (the “Consultant”)

WHEREAS

	(A) 	
      The Consultant has agreed to advise, for a period of two
      years, the Company in the area of business development in connection with
      the business of the evaluation, acquisition and development of patents in
      the field of healthcare drug treatments offered by the Company and its
      associated companies (the “Business”).

	 	 
	(B) 	
      The parties have agreed that this agreement shall govern
      the terms of the services to be provided by the
  Consultant.

OPERATIVE PROVISIONS

	1. 	
      DURATION OF APPOINTMENT

	 	 	 
	1.1 	
      The Consultant shall continue to advise the Company on
      the terms of this agreement for a term from 7th December 2007 for a fixed
      term of two years unless or until terminated under the provisions of
      Clause 5.1 hereafter. The parties may extend the term of this Agreement
      for a further term of twelve months by mutual written agreement.

	 	 	 
	2. 	
      DUTIES

	 	 	 
	2.1 	
      The services of the Consultant shall comprise the giving
      of advice to the Company in the area of business development via the Board
      of the Company in connection with the Business and such other advisory
      services as may be agreed between the parties.

	 	 	 
	2.2 	
      The Consultant shall be accountable to the Company’s CEO
      and shall in performance of his role hereunder:

	 	 	 
		(a) 	
      Use his best endeavours to advise the Company via the
      Board when required in the areas described in 2.1 above;

	 	 	 
		(b) 	
      Conduct such travelling as shall be reasonably necessary
      to advise the Business;

	 	 	 
		(c) 	
      Carry out his duties in good faith and in proper and
      efficient manner;

	 	 	 
		(d) 	
      Conduct himself with propriety and not bring the Company
      into disrepute;

	 	 	 
		(e) 	
      Not have any authority to bind the Company in any way and
      shall not hold himself out either by words or conduct as being the agent
      of the Company;

	 	 	 
		(f) 	
      Act as a member of the Company, attending meetings where
      possible of such board when held in London or other cities in Europe;
      and

	 	 	 
		(g) 	
      Not misrepresent the Company to any
  person.

	
3. 		
FEES

	
	 	 	 	 
	
3.1 		
The Consultant shall be not entitled to receive from the Company any fixed cash fees for the services outlined herein, but shall be entitled to receive reimbursement of any and all expenses properly incurred in performing his
duties hereunder.

	
	 	 	 	 
	
3.2 		
The Consultant will receive, as payment in kind from the Company, in respect of his services under this Agreement, the issue to him of 30,000 shares in the Company. The Consultant undertakes that the shares will by issued under US
securities laws and will be subject to restrictions as set out by the securities and exchanges commission.

	
	 	 	 	 
	
4. 		
CONFIDENTIALITY

	
	 	 	 	 
	
4.1 		
The Consultant shall not, either during the continuance of this agreement or for not less than one year thereafter make personal use of or divulge to any other company, firm or person any confidential information received by
virtue of this Agreement or any market or other information relating to the business of the Company.

	
	 	 	 	 
	
5. 		
TERMINATION

	
	 	 	 	 
	
5.1 		
This Agreement may be terminated by either party giving the other three month’s written notice in accordance with Clause 1.

	
	 	 	 	 
		
This Agreement may be terminated in accordance with clause 1 hereof by either party giving one month’s written notice to the other party in the following circumstances;

	
	 	 	 	 
		
(a) 		
if either party commits or causes to be committed any material breach of its obligations under the Agreement provided that in the case of a breach capable of remedy the non-defaulting party shall have first given written notice to
the defaulting party specifying the breach complained of any requiring the same to be remedied within a reasonable period of time from notification thereof and the defaulting party shall have failed to comply therewith;

	
	 	 	 	 
		
(b) 		
if either party commits an act of insolvency, including:

	
	 	 	 	 
			
i. 		
making a general assignment for the benefit of, or entering into a reorganisation, arrangement, or composition with creditors, or

	
	 	 	 	 
			
ii. 		
admitting in writing that it is unable to pay its debts as they become due, or

	
	 	 	 	 
			
iii. 		
seeking, consenting to or acquiescing in the appointment of any trustee, administrator, receiver or liquidator or analogous officer of it or any material part of its property, or

	
	 	 	 	 
			
iv. 		
the presentation or filing of a petition in respect of it (other than by the other party to this Agreement in respect of any obligation under this Agreement) in any court or before any agency alleging or for the bankruptcy,
winding-up or insolvency of such party (or any analogous proceeding) or seeking any reorganisation, arrangement., composition, readjustment, administration, liquidation, dissolution or similar relief under any present or future stature, law or
resolution, such petition (except in the case of a petition for winding-up or any analogous proceeding in respect of which no such 30 day period shall apply not having been stayed or dismissed within 30 days of its filing;

	

		 	v. 	 the appointment of a receiver, administrator, liquidator
        or trustee or analogous officer of such party over all or any material
        part of such party’s property.

	 	 	 	 
	6. 	 ASSIGNMENT

	 	 	 	 
	6.1 	 This Agreement may not be assigned by either
        party without the prior written consent of the other party.

	 	 	 	 
	7. 	 AMENDMENT

	 	 	 	 
	7.1 	 This Agreement may not be amended except by
        the written consent of both parties.

	 	 	 	 
	8. 	 NOTICES

	 	 	 	 
	8.1 	 All notices required to be delivered under
        this agreement by one party to the other shall be sent in writing to the
        addresses as are set forth at the beginning of this agreement, or such
        address as the parties shall thereafter provide to each other in writing.

	 	 	 	 
	9. 	 GOVERNING LAW

	 	 	 	 
	9.1 	 The Agreement shall be governed by and constructed
        in accordance with the laws of the United States of America. Any disputes
        which may arise out of this Agreement, if not resolved amicably between
        the parties, shall be settled finally before the courts of the United
        States of America.

DATED THE 7th DAY OF December, 2007 

ATTESTATIONS

Signed as a deed by a DIRECTOR or the COMPANY SECRETARY on
behalf of

	  	/s/ David Cooper 
	NEXTGEN BIOSCIENCE INC. 	 
    
	  	  
	Signed as a deed by 	/s/ Dr. Rolf Witte 
	Dr. Rolf Witte

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00135-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00135-of-00352.parquet"}]]